Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Current Oncology | Free Full-Text | Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
Diapositive 1
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect
Active Trials - Head and Neck Cancer Alliance
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma - ScienceDirect
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
ESMO 2020 Preview, part 2: new and/or notable | BLU Ampersand, Inc.
Cancers | Free Full-Text | Changing Landscape of Systemic Therapy in Biliary Tract Cancer
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1 FGFR2 or FGFR3- (FUZE Clinical Trial) | Clinical Research Trial Listing ( Solid Tumor ) ( NCT03834220 )
Cells | Free Full-Text | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer | Nature Reviews Clinical Oncology
PDF) New clinical trial designs in the era of Precision Medicine
FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review
FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020
Active Trials - Head and Neck Cancer Alliance
Frontiers | Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review
Cancers | Free Full-Text | Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
